New drug with chemo for newly diagnosed osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests adding trilaciclib to standard chemotherapy before surgery for patients with newly diagnosed, high-grade osteosarcoma. Trilaciclib may help protect healthy cells during chemo treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with classic, high-grade osteosarcoma that has not spread widely (stage II or III).
- You have not received any prior chemotherapy or other systemic cancer treatment.
- You are able to perform daily activities with little to no help (ECOG 0 or 1).
- You have at least one tumor that can be measured on a CT scan.
- You agree to use effective birth control during treatment and for 6 months after the last dose.
- Your vital organs (like heart, liver, kidneys) are working well enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the combination of two drugs, apatinib (a targeted therapy) and liposomal irinotecan (a chemotherapy), can help people with osteosarcoma that has not responded to standard treatments or has spread. The goal is to see if the combination can shrink tumors or slow the disease.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests abemaciclib (a cancer medicine) in adults with advanced, unresectable bone or soft-tissue sarcoma that has certain gene changes in the “CDK pathway.” It aims to shrink tumors or slow growth in people whose tumors match the study’s biomarker and lab requirements.
This Phase 2 trial studies whether surufatinib combined with chemotherapy given before surgery can shrink osteosarcoma and improve outcomes. It may help by attacking the tumor from more than one angle before the main treatment step.
This trial tests a drug called trilaciclib, given along with standard chemotherapy (etoposide plus cisplatin or carboplatin) and radiation. The goal is to see if trilaciclib can help protect your bone marrow from the side effects of treatment.
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.